C

Credo

Automates medical record retrieval for providers

Overview

Credo Health offers an automated medical record retrieval platform for healthcare providers and payers that uses interoperability standards to automate the end-to-end process of obtaining patient records. The system connects to multiple data sources, gathers records, and delivers a complete, accurate set of information before the first visit so clinicians can start with a full view of the patient. It differentiates itself through end-to-end automation centered on standardized interoperability and a subscription-based model that may include premium features. The company aims to improve compliance, clinical understanding, and patient outcomes by ensuring timely, comprehensive records at the point of care.

Work here?Claim your company

About Credo

Simplify's Rating
Why Credo is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & AnalyticsEnterprise SoftwareHealthcare

Company Size

11-50

Company Stage

Seed

Total Funding

$8.3M

Headquarters

Denver, CO

Founded

2021

Get referred to Credo

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • Credo says PreDx retrieves records for 98% of patients before first visits.
  • The Vim partnership expands point-of-care distribution across thousands of connected provider organizations.
  • A 2024 seed round raised $5.25 million from FCA Venture Partners and others.

What critics are saying

  • Vendor-reported outcomes lack independent validation, exposing pricing to skeptical buyers.
  • Manual retrieval through telephone, portals, and fax preserves labor costs and delays.
  • If TEFCA incumbents bundle retrieval and summaries inside EHRs, Credo's standalone platform loses demand.

What makes Credo unique

  • PreDx combines record retrieval, human curation, and AI summaries before first visits.
  • Credo integrates TEFCA, Carequality, CommonWell, eHealth Exchange, and fallback fax retrieval.
  • Named customers include ChenMed, Clover Health, Imperial Health, P3, and Bluezones.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$8.3M

Above

Industry Average

Funded Over

2 Rounds

Seed funding is usually the first official round after pre-seed, when a startup has a prototype or concept. It’s typically used to develop the product, test the market, and start building the team. Investors here are often angel investors or early-stage venture capitalists.
Seed Funding Comparison
Above Average

Industry standards

$3.3M
$2M
$2.3M
$3M
$5.3M

Benefits

  • Remote Work Options

Growth & Insights and Company News

6 month growth

-10%

1 year growth

0%

2 year growth

3%
Credo Semiconductor
Sep 21st, 2026
Credo Completes Acquisition of DustPhotonics

Expands Optical Connectivity Portfolio to Include Silicon Photonics Photonic Integrated Circuits Credo Technology Group Holding Ltd (Credo) (NASDAQ: CRDO), an innovator in providing connectivity at scale through fast, reliable, and energy-efficient system solutions, today announced that it has completed its acquisition of DustPhotonics. DustPhotonics brings industry-leading silicon photonics photonic integrated circuit (SiPho PIC) technology for optical connectivity, deepening Credo’s optical interconnect portfolio across 800G, 1.6T, and 3.2T near-packaged optics (NPO) and co-packaged optics (CPO). With this technology, Credo is now positioned with a vertically integrated connectivity stack spanning SerDes, digital signal processing (DSP), silicon photonics, and system integration for scale-out and scale-up networks — addressing both electrical and optical interconnects across the full AI infrastructure buildout. Credo announced that it has completed its acquisition of DustPhotonics.

StockTitan
Apr 13th, 2026
A $750M deal gives Credo silicon photonics tech for AI networks

DustPhotonics adds PIC technology for 400G to 3.2T optics. Credo sees $500M+ optical revenue in fiscal 2027; closing is expected in Q2 2026.

PR Newswire
Jan 5th, 2024
Credo Health Announces Oversubscribed $5.25 Million Series Seed Funding

"This investment is a testament to our commitment to fully support providers with the technology they need to succeed in value-based care," says Credo Founder and CEO Carm Huntress. .

PR Newswire
Mar 27th, 2023
Credo Unveils Predx - The First Pre-Encounter Patient Summary Solution

Our solution not only improves patient outcomes, but directly affects providers' ability to accurately diagnose complex patients and speed up time to effective treatment. .

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Credo right now.

Find jobs on Simplify and start your career today

We update Credo's jobs every few hours, so check again soon!Browse all jobs